Hillsdale Investment Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Hillsdale Investment Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$368K	Buy	+5,760	New	+$299K	0.01%	497
2026 Q1	–	Sell	-224,074	Closed	-$9.24M	–	722
2025 Q4	$9.24M	Sell	224,074 -1,300	-0.6%	-$52.1K	0.26%	67
2025 Q3	$8.75M	Buy	225,374 +24,800	+12%	+$806K	0.26%	64
2025 Q2	$5.55M	Buy	+200,574	New	+$5.11M	0.2%	132
2023 Q1	–	Sell	-244,017	Closed	-$3.66M	–	612
2022 Q4	$3.66M	Buy	+244,017	New	+$3.55M	0.31%	123

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Hillsdale Investment Management's KNSA Position: Q2 2026 in Review

Hillsdale Investment Management opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 5,760 shares worth $368K. The stake represents 0.01% of the portfolio and ranks #497 among its holdings. This is a return to the name: Hillsdale Investment Management previously reported a position in KNSA as recently as Q4 2025.

Hillsdale Investment Management first reported a position in KNSA in Q4 2022 and has held it in 5 quarters since. The position peaked at $9.24M in Q4 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Hillsdale Investment Management held 5,760 shares of Kiniksa Pharmaceuticals worth $368K as of Q2 2026.
Kiniksa Pharmaceuticals was a new Hillsdale Investment Management position in Q2 2026.
Kiniksa Pharmaceuticals made up 0.01% of Hillsdale Investment Management's portfolio in Q2 2026, its #497 holding.
Hillsdale Investment Management first reported a position in Kiniksa Pharmaceuticals in Q4 2022 and has held it in 5 quarters since.
Hillsdale Investment Management's Kiniksa Pharmaceuticals position peaked at $9.24M in Q4 2025.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.